Newly Activated Clinical Trials

The following studies were recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

Click the study links below to learn details regarding the study on clinicaltrials.gov. For more information or questions about a study, email cancertrials@uic.edu or call 312-355-5112.

Protocol Title: SentiNOT 2.0: Breast Cancer: Use of Superparamagnetic Iron Oxide Tracer to Avoid Unnecessary Sentinel Node Biopsies 

PI: Diane Drugas, MD
Sponsor: Uppsala University

Protocol Title: GS-US-592-6238: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1

PI: Abiola Ibraheem, MD
Sponsor: Gilead Sciences 

Protocol Title:GS-US-592-6173: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1

PI: Abiola Ibraheem, MD

Sponsor: Gilead Sciences